Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Next Previous
Trial Profile

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Registrational
  • Acronyms ASSURE
  • Sponsors CymaBay Therapeutics; Gilead Sciences

Most Recent Events

  • 07 May 2025 According to a Gilead Sciences Media Release, data from this trial were presented at the European Association for the Study of the Liver (EASL) Congress 2025
  • 07 May 2025 Results presented in the Gilead Sciences Media Release
  • 29 Apr 2025 According to a Gilead Sciences Media Release, results from a subgroup analysis of this trial will be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top